{"id":"W4233507620","doi":"10.1158/1538-7445.sabcs18-ct200","title":"Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","year":2019,"lang":"en","type":"article","venue":"Clinical Trials","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"","keywords":"Atezolizumab; Carboplatin; Paclitaxel; Oncology; Nab-paclitaxel; Internal medicine; Medicine; Progression-free survival; Overall survival; Chemotherapy; Cancer; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003336604,0.001647906,0.002171036,0.0005674062,0.0005148015,0.00128492,0.001317806,0.001741148,0.01305934],"category_scores_gemma":[0.002796363,0.0007513941,0.002708121,0.0007149639,0.001199345,0.0009704101,0.0007539554,0.004856655,0.001400236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001533172,"about_ca_system_score_gemma":0.002887537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009834967,"about_ca_topic_score_gemma":0.003203646,"domain_scores_codex":[0.9985415,0.0009602507,0.00006570776,0.0001566971,0.0001389132,0.0001370055],"domain_scores_gemma":[0.9977772,0.0005589663,0.0005511275,0.0001885638,0.0001175527,0.0008066974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9622992,0.00820185,0.001787409,0.0004532839,0.001259874,0.00007383467,0.00005195324,0.0007613359,0.005956418,0.0001307615,0.00383491,0.01518918],"study_design_scores_gemma":[0.8678535,0.11799,0.008396355,0.00004424064,0.001325455,0.0001364042,0.00001708061,0.0008880596,0.001269894,0.0002238508,0.001829669,0.00002541367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9722662,0.002655912,0.001235343,0.001070686,0.0001571177,0.006650996,0.01048647,0.0002687568,0.005208301],"genre_scores_gemma":[0.9746013,0.001160397,0.001858685,0.001438622,0.0002472064,0.00475745,0.01258111,0.00008310891,0.003272065],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01305934,"threshold_uncertainty_score":0.04368788,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07989084445208605,"score_gpt":0.4983019247232041,"score_spread":0.4184110802711181,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}